Magnetoencephalography as a Biomarker for HIV-Associated Neurocognitive Disorder

脑磁图作为 HIV 相关神经认知障碍的生物标志物

• 批准号: 8469618
• 负责人: JAMES T. BECKER
• 金额: $ 22.02万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-21 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8469618
• 关键词: AIDS Dementia Complex; AIDS neuropathy; Activities of Daily Living; Address; Affect; Area; Automobile Driving; Biological; Biological Markers; Brain; Caring; Cerebrovascular Circulation; Chronic; Clinical; Cognition; Cognition Disorders; Cognitive; Cognitive deficits; Country; Data; Dementia; Development; Differential Diagnosis; Disease; Emerging Technologies; Employment; Enrollment; Epilepsy; Exploratory/Developmental Grant; Eye; Functional Magnetic Resonance Imaging; Functional disorder; Funding; Goals; HIV; Image; Impaired cognition; Individual; Life; Longitudinal Studies; MRI Scans; Magnetic Resonance Imaging; Magnetoencephalography; Measures; Medical; Methods; Modality; Modeling; Morphologic artifacts; Movement; Neurocognitive; Neurons; Neuropsychological Tests; Outcome; Participant; Pathology; Patients; Performance; Physiologic pulse; Pilot Projects; Population; Positron-Emission Tomography; Price; Publishing; Recovery; Relative (related person); Research; Research Project Grants; Resolution; Rest; Scanning; Screening procedure; Secondary to; Series; Signal Transduction; Signs and Symptoms; Spin Labels; Study Subject; Synapses; Techniques; Technology; Testing; Therapeutic; Woman; base; blood oxygen level dependent; design; imaging modality; magnetic field; medication compliance; meetings; memory recognition; neurobehavioral; neuroimaging; neuropsychological; novel; research clinical testing; response; tool; volunteer; white matter damage

DESCRIPTION (provided by applicant): HIV disease is becoming more of a chronic condition in countries with good access to medical care. In the area of NeuroAIDS there is no acknowledged, useful biomarker for the cognitive disorder associated with HIV disease (i.e., HIV-Associated Neurocognitive Disorder (HAND)), independent of the cognitive tests. Magnetic resonance imaging and positron emission tomography have been tried, but have yet to fulfill their promise {Price, 2007 #6509}. One emerging technology that has only recently been applied to HIV Disease - by our research team - is magnetoencephalography (MEG). MEG is a non-invasive technique for measuring neuronal activity by recording the magnetic fields induced by synchronized neuronal currents. MEG has the highest spatial and temporal resolution of any current neuroimaging technology, and is used most commonly in the clinical evaluation of patients with seizure disorders, and by cognitive neuroscientists to investigate electrophysiological responses of the CNS. Unlike techniques such as functional MRI, MEG does not rely on the blood-oxygen level dependent response in order to generate responses. Thus, it will be very important to determine whether MEG can identify abnormal brain function in HIV Disease - especially when cognitive dysfunction is mild and not yet affecting activities of daily living. Our team has demonstrated that we can differentiate infected from uninfected study subjects, that there may be an independent MEG-derived variable that is sensitive to cognitive dysfunction, and that MEG signals are stable over a 6-month period. The preliminary research was conducted in the context of an R03-funded study, so the overall goal of this new R21 research project is to obtain the necessary additional data from 30 infected individuals (and 10 controls) to finalize the design for a larger, longitudinal study. These data will allow us to begi to characterize the neurocognitive outcomes of HIV Disease using a highly sensitive electrophysiological tool. PUBLIC HEALTH RELEVANCE: HIV infected patients can still have abnormalities in cognition ranging from the more common mild deficits, to the less common, but more devastating dementia. What is missing in the field of NeuroAIDS is a tool that will provide information about the biological state of the brain that is related to the cognitive impairment. We propose to study Magnetoencephalography (MEG) as a potential biomarker. In this project, we will find out whether it is feasible to use MEG in patients with NeuroAIDS, and we will decide exactly how to design a larger, longitudinal study.

描述（由申请人提供）：在获得良好医疗服务的国家，艾滋病毒疾病越来越成为慢性病。在神经助剂领域，与与HIV疾病相关的认知疾病（即HIV相关的神经认知障碍（HARD））没有公认的，有用的生物标志物，与认知测试无关。已经尝试了磁共振成像和正电子发射断层扫描，但尚未履行其诺言{Price，2007＃6509}。我们的研究团队（MEG）直到最近才针对HIV疾病的一项新兴技术。 MEG是一种通过记录由同步神经元电流诱导的磁场来测量神经元活性的非侵入性技术。 MEG在任何当前的神经影像技术中具有最高的空间和时间分辨率，并且最常用于癫痫发作疾病患者的临床评估中，以及通过认知神经科学家研究中枢神经系统的电生理反应。与功能性MRI等技术不同，MEG不依赖血氧水平依赖性反应来产生反应。因此，确定MEG是否可以识别艾滋病毒疾病中的脑功能异常非常重要 - 尤其是当认知功能障碍轻度且尚未影响日常生活活动时。 我们的团队已经证明，我们可以将感染与未感染的研究对象区分开来，可能会有一个独立的MEG衍生变量对认知功能障碍敏感，并且MEG信号在6个月内稳定。初步研究是在一项R03资助的研究的背景下进行的，因此该新的R21研究项目的总体目标是从30个受感染的个体（和10个对照）中获得必要的其他数据，以最终确定一项较大纵向研究的设计。这些数据将使我们能够使用高度敏感的电生理工具来表征HIV疾病的神经认知结果。 公共卫生相关性：感染艾滋病毒感染的患者的认知异常，从更常见的轻度赤字到较不常见但更具毁灭性的痴呆症。神经辅助领域缺少的是一种工具，它将提供有关与认知障碍有关的大脑生物状态的信息。我们建议将磁脑摄影（MEG）作为潜在的生物标志物研究。在这个项目中，我们将找出在神经助剂患者中使用MEG是否可行，并且我们将确切决定如何设计更大的纵向研究。